干扰素α1b联合孟鲁司特钠治疗小儿喘息性支气管炎的临床疗效及对预后的影响

Clinical effec of interferon α1b combined with montelukast sodium on pediatric asthmatic bronchitis and its effect on prognosis

目的分析干扰素α1b联合孟鲁司特钠治疗小儿喘息性支气管炎的临床疗效及其对预后的影响。方法选取我院2016年3月至2018年2月收治的120例喘息性支气管炎患儿作为研究对象,将其随机分为常规组和治疗组,各60例。常规组实施利巴韦林治疗,治疗组在常规组基础上采用干扰素α1b联合孟鲁司特钠治疗,比较两组患儿的治疗效果、复发情况及不良反应发生情况。结果治疗后,两组患儿FEV_1、FEV_1%均显著升高,且治疗组高于常规组(P<0.05);治疗组的临床症状消失时间显著短于常规组(P<0.05);治疗组的显效率及复发率均显著优于常规组(P<0.05);两组患儿不良反应总发生率比较无明显差异(P>0.05)。结论采用干扰素α1b联合孟鲁司特钠治疗小儿喘息性支气管炎的疗效显著,值得临床推广。

Objective To analyze the clinical effect of interferon α1b combined with montelukast sodium on childrenwith asthmatic bronchitis and its effect on prognosis. Methods From March 2016 to February 2018, 120 children withasthmatic bronchitis treated in our hospital were randomly divided into routine group and treatment group, with 60 cases ineach group. The routine group was treated with ribavirin, and the treatment group was treated with interferon α1b combinedwith montelukast sodium on the basis of the routine group. The therapeutic effects, recurrence and the incidence of adversereactions of the two group were compared. Results After treatment, the FEV1, FEV1% in the two groups significantlyincreased, and those of the treatment group were higher than the routine group （P 〈0.05）; the clinical symptomsdisappearance time in the treatment group was significantly shorter than that in the routine group （P〈0.05）; the expliciteffective rate and recurrence rate in the treatment group were better than those in the routine group （P〈0.05）; there was nosignificant difference in the total incidence of adverse reactions between the two groups （P〉0.05）. Conclusion Thetherapeutic effect of interferon α1b combined with montelukast sodium on children with asthmatic bronchitis is significant,which is worthy of clinical promotion.